Pfizer and partner BioNTech said three COVID-19 shots protect kids under 5.
Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week.
A small number of COVID-19 patients are relapsing after taking Pfizer's antiviral pill, raising questions about the drug at the center of the U.S. response effort.
Pfizer is testing three extra-small doses of its vaccine in children under 5 after two shots didn't prove quite strong enough.
The pharmaceutical company, in making its request, cited a small study that found that children given a booster had a 36-fold increase in virus-fighting antibodies.
This fourth coronavirus vaccine dose would be optional, and federal health officials aren't currently recommending it for everyone in this age group.
It would add a fourth dose to the vaccination regimen in an effort to provide maximum protection to the over-65 population.
Pfizer CEO Albert Bourla brought up the possibility of a second COVID-19 booster shot as cases of coronavirus continue to dip in some areas.
Pharmaceutical head Albert Bourla said it is preparing to submit data to the FDA that would show the effectiveness of receiving a second booster shot.
The new data comes a day after a study of New York children suggested the vaccine may not be as effective in 5- to 11-year-olds as in older kids.